Browse by author
Lookup NU author(s): Christopher Huggins,
Emeritus Professor John Kirby,
Professor James Shaw
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background: Plasmid DNA vectors offer the potential of safe gene therapy avoiding viral vector-mediated toxicity and immunogenicity. As plasmid DNA is bacterial in origin, presence of bacterial lipopolysaccharide (LPS) or unmethylated CpG dinucleotides may stimulate host innate immunity. Methods: Primary cultures of mouse and rat dendritic cells were established and incubated with bacterial lipopolysaccaride; immunostimulatory CpG oligodeoxynucleotide; control GpC oligodeoxynucleotide; and a range of (pVR1012) plasmids encoding transgenes with increasing CpG content (wild-type and mutant human preproinsulin; non-mammalian eukaryotic eGFP reporter gene; and bacterial β-galactosidase reporter gene). IL-12 secretion was assayed to determine in vitro plasmid immunogenicity. Local inflammatory response following intramuscular injection of these plasmids, with or without a non-ionic carrier SP1017, was characterised in vivo. Results: Dose-responsive LPS and CpG stimulation of IL-12 secretion from dendritic cells was demonstrated. All plasmids induced significant IL-12 secretion in comparison to control unstimulated cells. The β-galactosidase plasmid had highest CpG content and induced significantly higher IL-12 secretion than constructs containing a eukaryotic transgene. Injection of rat muscle with the β-galactosidase construct induced greater inflammatory response than human preproinsulin constructs. This was further enhanced by SP1017. At 2 days post-injection, monocyte/macrophage injection site infiltration predominated with CD8-positive lymphocytes predominating at 7 days. There was no evidence of transgene expression in infiltrating immune cells. Conclusions: Dendritic cell immunostimulation may be employed as an in vitro bioassay of innate immmune response to plasmid DNA vectors during evaluation for clinical gene theraphy. Copyright © 2007 John Wiley & Sons, Ltd.
Author(s): Ratanamart J, Huggins CG, Kirby JA, Shaw J
Publication type: Article
Publication status: Published
Journal: Journal of Gene Medicine
ISSN (print): 1099-498X
ISSN (electronic): 1521-2254
Publisher: John Wiley & Sons, Inc.
PubMed id: 17595049
Altmetrics provided by Altmetric